|
|
xi | |
Preface |
|
xix | |
|
PART I BACKGROUND AND INTRODUCTION |
|
|
1 | (84) |
|
Restenosis following percutaneous coronary interventions: a clinical problem |
|
|
3 | (12) |
|
|
|
|
|
|
|
|
|
Histopathology of restenosis |
|
|
15 | (10) |
|
|
|
Cellular mechanisms of restenosis: conventional dogma and novel theory |
|
|
25 | (14) |
|
|
Molecular basis of restenosis and potential therapeutic targets |
|
|
39 | (8) |
|
|
|
|
Principles of continuum pharmacokinetics in stent-based drug elution |
|
|
47 | (10) |
|
|
|
Importance of the toxic/therapeutic window |
|
|
57 | (8) |
|
|
|
|
65 | (10) |
|
|
|
The importance of the drug platform: coated, uncoated, sleeves, and new concepts |
|
|
75 | (10) |
|
|
|
PART II DRUG-STENT PROGRAMS |
|
|
85 | (280) |
|
Rapamycin structure and mechanism of action |
|
|
87 | (6) |
|
|
|
Sirolimus-coated stent: preclinical studies |
|
|
93 | (10) |
|
|
|
|
Nonrandomized registries for de novo lesions (FIM) and in-stent restenosis |
|
|
103 | (6) |
|
|
|
|
|
|
|
|
109 | (12) |
|
|
The SIRIUS, E-SIRIUS, and C-SIRIUS trials |
|
|
121 | (12) |
|
|
|
Sirolimus-eluting coronary stent in high-risk patients with complex lesions: subset data from controlled clinical trials and registries |
|
|
133 | (12) |
|
|
Local vascular delivery of paclitaxel: background, mechanisms, and pharmacodynamic properties |
|
|
145 | (8) |
|
|
|
|
Preclinical experience with the paclitaxel-eluting stent: the Boston Scientific Program |
|
|
153 | (4) |
|
|
|
The Quanam drug-eluting stent and the SCORE trial |
|
|
157 | (8) |
|
|
Initial experiences with paclitaxel-eluting stents for treatment of de novo as well as in-stent restenotic lesions: TAXUS I and TAXUS III |
|
|
165 | (8) |
|
|
|
The Boston Scientific Taxus trials |
|
|
173 | (12) |
|
|
|
Local delivery of paclitaxel as a stent coating: biology and clinical implications |
|
|
185 | (6) |
|
|
Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT) |
|
|
191 | (10) |
|
|
Patency Pilot study: a negative trial, in context |
|
|
201 | (4) |
|
|
Paclitaxel-eluting stents---the ELUTES trial |
|
|
205 | (4) |
|
|
|
Vascular Endothelial Growth Factor (VEGF)-eluting stents |
|
|
209 | (6) |
|
|
|
The Millennium Matrix™ Coronary Stent |
|
|
215 | (12) |
|
|
|
|
The Conor drug delivery stent |
|
|
227 | (6) |
|
|
|
Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study (the ACTION trial) |
|
|
233 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Guidant deliver II study: prospective, nonrandomized, multicenter evaluation of the ACHIEVE™ paclitaxel-eluting coronary stent system in the treatment of lesions with high risk of revascularization due to restenosis |
|
|
243 | (2) |
|
|
Guidant deliver clinical trial: prospective, randomized, single-blinded, parallel-group (two-arm), multicenter, clinical evaluation of the RX ACHIEVE™ drug-eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions |
|
|
245 | (2) |
|
|
|
Batimastat: mode of action, preclinical, and clinical studies |
|
|
247 | (14) |
|
|
|
|
|
|
The prevention and treatment of in-stent restenosis---the current challenge for coronary intervention |
|
|
261 | (12) |
|
|
|
Dexamethasone: mode of action, preclinical, and clinical studies |
|
|
273 | (12) |
|
|
|
|
|
|
|
|
17β-estradiol-eluting stents---a potential therapy in the prevention of restenosis |
|
|
285 | (10) |
|
|
|
|
|
An advanced antisense (AVI-4126) for local and stent-based delivery for prevention of restenosis after PCI (current status and future developments) |
|
|
295 | (10) |
|
|
|
|
|
|
The Endeavor Drug-Eluting Stent program |
|
|
305 | (8) |
|
|
Terumo statin releasing stent (preclinical results) |
|
|
313 | (10) |
|
|
|
|
|
Duraflex™ Drug-Eluting Coronary Stent System |
|
|
323 | (6) |
|
|
|
|
|
|
|
Genous™ Bio-engineered R stent™: development and the HEALING clinical evaluations |
|
|
329 | (12) |
|
|
|
|
|
|
Everolimus-eluting stents |
|
|
341 | (8) |
|
|
|
Contemporary state of drug-eluting stents |
|
|
349 | (16) |
|
|
|
|
Index |
|
365 | |